Evidence map›Paper›PMID 40851023›Full record

ArticleScientific reports2025

The expression of transmembrane channel-like 5 in gastric cancer and its impact on tumor progression.

Yucai Wei, Jiaxing Zhang, Xiaomei Li, Weijing Zhu, Peng Zhang, Huijuan Cheng, Qian Chen, Zhongjie Wen, Huanhuan Liu, Lei Zhao and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Yucai Wei *Cancer Center, The Second Hospital of Lanzhou University, Lanzhou, China.
Jiaxing Zhang *Gansu Province Key Laboratory of Environmental Oncology, The Second Hospital of Lanzhou University, 82 Cuiyingmen, Lanzhou, 730030, Gansu, China.
Xiaomei Li *Gansu Province Key Laboratory of Environmental Oncology, The Second Hospital of Lanzhou University, 82 Cuiyingmen, Lanzhou, 730030, Gansu, China.
Weijing ZhuGansu Province Key Laboratory of Environmental Oncology, The Second Hospital of Lanzhou University, 82 Cuiyingmen, Lanzhou, 730030, Gansu, China.
Peng ZhangThe Second Clinical Medical School, Lanzhou University, Lanzhou, China.
Huijuan ChengGansu Province Key Laboratory of Environmental Oncology, The Second Hospital of Lanzhou University, 82 Cuiyingmen, Lanzhou, 730030, Gansu, China.
Qian ChenThe Second Clinical Medical School, Lanzhou University, Lanzhou, China.
Zhongjie WenThe Second Clinical Medical School, Lanzhou University, Lanzhou, China.
Huanhuan LiuThe Second Clinical Medical School, Lanzhou University, Lanzhou, China.
Lei ZhaoGansu Province Key Laboratory of Environmental Oncology, The Second Hospital of Lanzhou University, 82 Cuiyingmen, Lanzhou, 730030, Gansu, China. ery_zhaoleryy@lzu.edu.cn.
Yumin LiCancer Center, The Second Hospital of Lanzhou University, Lanzhou, China. liym@lzu.edu.cn.

Funding

Cuiying Scientific Training Program for Undergraduates of the Second Hospital & Clinical Medical School, Lanzhou University CYXZ2022-36Fundamental Research Funds for the Central Universities of Lanzhou University lzujbky-2022-sp08National Natural Science Foundation of China 82260612
6 · The paper itself

Abstract

Gastric cancer (GC) is a prevalent malignancy and one of the leading causes of cancer-related mortality worldwide. The role of transmembrane channel-like 5 (TMC5) in GC remains unknown. In this study, we analyzed the expression of TMC5 in GC using a multi-faceted approach, including analysis of public databases, immunohistochemical assays, and Western blot analyses. Our results demonstrated that TMC5 was overexpressed in GC tissues and cell lines, which was associated with poor prognosis and various clinical characteristics. We observed that the mutation rates of TMC5 in GC were low, and its methylation status was inversely related to its expression levels. Furthermore, functional assays demonstrated that TMC5 promoted GC cell proliferation, migration, and invasion in vitro, as well as tumor growth and metastasis in vivo. Furthermore, the TMC5 expression level was positively correlated with stemness and chemotherapy resistance in GC. Additionally, TMC5 was associated with multiple immune cell infiltration levels, immunotherapy response and immune checkpoint genes. Subsequently, the co-expression genes of TMC5 in GC were screened and verified by qRT-PCR. Gene set enrichment analysis showed that these genes were mainly involved in biosynthesis, metabolic pathways, and multiple classic cancer-related signaling pathways. In conclusion, our study reveals the important role of TMC5 in GC and provides potential new targets and strategies for the diagnosis and treatment of GC.

Indexed as

Gene Expression Regulation, NeoplasticStomach NeoplasmsAnimalsCell Line, TumorCell MovementCell ProliferationDisease ProgressionDNA MethylationFemaleHumansMaleMiceMiddle AgedPrognosisChemotherapy resistanceCo-expression genesGastric cancerImmunotherapy responsePrognosisTMC5

Identifiers

PMID40851023
PMCPMC12375704

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.